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Abstract
Dialysis-related amyloidosis is a serious complication for patients undergoing long-term
hemodialysis. Amyloid deposits composed of β2-microglobulin as the major constituent protein are
mainly localized in joints and periarticular bone and lead to destructive arthropathy. The
pathobiology of dialysis-related amyloidosis is still incompletely understood. Although recent
histologic studies have shown the accumulation of monocytes/macrophages around amyloid
deposits, the factor(s) causing their infiltration and pathologic involvement has yet to be fully
elucidated. Accumulating evidence suggests that β2-microglobulin modified with advanced glycation
end products has a key role in recruitment and activation of macrophages through an advanced
glycation end product receptor-mediated pathway. Thus, dialysis-related amyloidosis arthropathies
may result from progressive accumulation of advanced glycation end products in long-lived amyloid
linked to a heightened cellular response. Antagonism of the interaction between advanced glycation
end products and their receptors may be a relevant strategy for cellular inflammation in dialysis-
related amyloidosis.
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INTRODUCTION
Dialysis-related amyloidosis (DRA) is a serious
complication for patients with chronic renal failure, and
has been identified as a major cause of skeletal morbidity
in dialysis patients. Dialysis-related amyloidosis is
characterized by β2-microglobulin (β2M) amyloid
deposits, predominantly in osteoarticular structures, and
by a destructive arthropathy (1,2).
The pathogenesis of DRA is still incompletely
understood. Although recent histologic studies have
shown the accumulation of monocytes/macrophages
around amyloid deposits (3,4), the factor(s) causing their
infiltration and pathologic involvement has yet to be fully
elucidated. Because β2M is a major constituent of
amyloid fibrils, it has been the target molecule for many
studies attempting to elucidate the pathogenesis of DRA.
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Polymerization of high blood concentrations of intact
β2M per se has seemed an unlikely contributor to the
pathogenesis of DRA, because no correlation has yet
been found between serum levels of β2M and the
occurrence of DRA (5,6). Alternative possibilities are
suggested by the finding of several modified forms of
β2M in some amyloid specimens. This review focuses
on the modification of β2M with advanced glycation end
products (AGEs), and the implication of AGEs in
monocyte/macrophage recruitment and activation in
DRA.
Advanced glycation end product
modification of β2-microglobulin in
dialysis-related amyloidosis
Retention of the subunit protein β2M by patients with
chronic renal failure is presumed to be the basic
requirement for the initiation of β2M amyloid deposition
(7). The β-structure of the molecule suggests an intrinsic
capacity for the formation of amyloid fibrils and β2M
amyloid fibrils can be formed in vitro with high
concentrations of β2M (8). However, experimental
conditions required for amyloid fibril formation in vitro
were stringent and very different from those in human
joints. Therefore, investigators have considered the
possibility that β2M must be modified to precipitate as
fibrils.
An isoform of β2M with a more acidic isoelectric point
(acidic β2M) has been subsequently recognized in the
serum, ultrafiltrate, and amyloid deposits from patients
undergoing dialysis (9,10). More recently, it has been
demonstrated that a part of acidic β2M was attributable
to progressive glycation and oxidation (“glycoxidation”)
of the molecule through the nonenzymatic Maillard
reaction (11). Approximately 10% of acidic β2M consists
of Amadori products and less than 1% of irreversible
AGEs (12). Advanced glycation end product-modified
β2M has a unique cross-linking and chemotactic capacity
and thus has attracted considerable interest despite its
modest quantity in hemodialysis patients.
Advanced glycation end products are heterogeneous
structures containing a variety of specific epitopes.
Pentosidine (13), N∈-(carboxymethyl)lysine (14), and
imidazolone (15) are identified AGE structures present
on AGE-β2M in amyloid deposits. These substances are
markedly increased in uremic sera regardless of the
presence of diabetes (13-16).
The preferential location of AGE-modified β2M in
osteoarticular tissues has not been fully explained.
Hyperparathyroidism, aluminum accumulation, and iron
overload do not seem to be significant factors (17). The
biochemical composition of the osteoarticular structure
provides a more plausible explanation. The affinity of
β2M for some substances including native collagen and
glycosaminoglycans has been found in both in vitro and
in vivo studies (18,19). Our recent studies demonstrated
that significantly larger amounts of human β2M are bound
to immobilized AGE-modified type 1 collagen than to
unmodified type 1 collagen (20). The quantity of β2M
bound to AGE-modified collagen depends on the
concentration of both β2M and of AGEs contained in
collagen. Once bound to AGE-modified collagen, normal
β2M undergoes AGE modification in situ. These data
support the hypothesis that native β2M binds to AGE-
modified collagens and that AGE formation subsequently
occurs in the bound β2M. Consistent with our hypothesis,
a recent histologic study demonstrated that type 1
collagen, the most abundant matrix collagen in joints, is
modified with AGEs in elderly hemodialysis patients
without DRA. Advanced glycation end product
modification of the joint matrix is the only alteration
preceding amyloid formation (21).
We also observed that β2M interacts with various types
of AGE-modified collagen. However, AGE formation
in type IV collagen (collagen found in basement
membranes) is reduced compared with types I, II, and
III collagen (the predominant collagens in osteoarticular
tissues) under identical incubation conditions (20). The
relative ease of AGE formation of types I, II, and III
collagen may account for the observation that, early in
the course of DRA, amyloid deposits are localized
predominantly in joints and periarticular bone. Later in
the progression of DRA, amyloid deposition occurs in
basement membrane-containing structures, such as the
vasculature and gastrointestinal tract (22,23). It remains
unclear whether AGE-modified β2M formed in the
circulation is taken up into amyloid by intermolecular
cross-linking with amyloid fibrils. Increases in AGE-
modified collagen occur normally with aging. The
preferential binding of β2M to AGE-modified collagen
may account for the predilection of dialysis amyloidosis
for older patients (1,20).
Role of advanced glycation end product-
β2-microglobulin in joint inflammation
The most distinctive histologic feature of DRA is the
deposition of amyloid fibrils in the affected joint
structures, with adjacent chronic inflammatory reaction
characterized by monocytes/macrophages infiltration (3,
24). This is in contrast to light chain-derived and amyloid
A amyloidosis, in which few inflammatory cells are
juxtaposed to the amyloid deposits (25). Immuno-
histochemical analysis reveals that macrophages in
tenosynovial tissues express proinflammatory cytokines
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such as interleukin (IL)-1β and tumor necrosis factor
(TNF)-α ,  and chemokines such as monocyte
chemoattractant protein-1 (MCP-1) and macrophage
inflammatory protein-1. Many of these cells also express
leukocyte function-associated antigen-1 (CD11a/CD18),
macrophage-1 antigen (Mac-1, CD11b/CD18), and very
late antigen-4 (CD49d/CD29) on their surface (26). The
macrophage infiltration occurs mainly around blood
vessels or adjacent to the deposition of amyloid protein
(26). This observation suggests that the infiltrating
macrophages are recruited from peripheral blood and
primed in the tissue microenvironment.
Gross osteoarticular pathology and clinical symptoms
are incongruous; the histologic prevalence of joint DRA
reaches 21% within 2 years after the onset of
hemodialysis and typically precedes the onset of clinical
and radiologic signs by several years (27). In a large
histologic study, postmortem joint samples from dialysis
patients were examined by immunohistochemical
staining for DRA (27). These authors observed that early,
preclinical β2M amyloid deposits occur in cartilage and
subsequently extend to the joint capsule and synovium.
Neither macrophage infiltration nor bone destruction is
detectable at this early stage. However, at a later stage,
macrophages are recruited around the larger synovial and
capsular deposits. This stage is symptomatic and
accompanied by articular destruction and typical bone
erosion (28). The observation that macrophages are
associated with tissue destruction suggests a role for these
cells in the transformation of clinically silent amyloid
deposits into a symptomatic destructive arthropathy. For
example, the development of clinical symptoms of DRA,
such as arthralgias, might result from an inflammatory
recruitment and activation of macrophages into the joint
microenvironment.
How does the cellular inflammation occur in the joint?
Although β2M has been variably demonstrated as an
agonist for selected resident joint cells, like synoviocytes
(29), there is little evidence that suggests a direct
pathobiologic effect of β2M on monocytes/macrophages.
Furthermore, β2M deposition could be seen at an early
stage, but tissue inflammation and joint destruction are
late findings of DRA (28).
Recent studies have demonstrated that AGE-modified
proteins are endowed with biologic activities that can
partly account for the natural history and findings of
dialysis-associated arthropathies. Advanced glycation
end product-β2M enhances chemotaxis of monocytes and
stimulates macrophages to release bone-resorbing
cytokines, such as IL-1β, IL-6, and TNF-α (12,30). The
quantity of these pyrogenic cytokines secreted from
macrophages is sufficient to stimulate the synthesis of
collagenase in cultured human synovial cells (12) and
thus may contribute to progressive bone loss and
formation of bone cysts. Healing of amyloid bone cysts
may be attenuated by the inhibition of type 1 collagen
synthesis by fibroblasts exposed to AGE-β2M (31).
Monocyte chemotaxis and TNF-α production induced
by AGE-β2M can be inhibited by blockade of the receptor
for AGEs (RAGE), suggesting that the biologic effects
of AGE-β2M on monocytes/macrophages are mediated
by RAGE (32). Increasing evidence suggests that
progressive AGE modification might occur in situ after
deposit ion of β2M (20,33),  and AGE-β2M is
preferentially detected in advanced amyloid deposits
(21). The latter finding is especially relevant, because
other forms of acidic β2M (like deaminated β2M and early
Amadori β2M), are biologically inert (12). Therefore,
the clinical manifestations of DRA may result from
progressive AGE transformation of poorly catabolized,
and thus long-lived, amyloid deposits.
A balance between recruitment and constitutive death
of inflammatory cells regulates the local inflammatory
response. We therefore evaluated the effects of AGE-
β2M on monocyte survival and maturation. Via a RAGE-
mediated pathway, AGE-modified β2M, but not
unmodified β2M, significantly delayed constitutive
apoptosis of human peripheral blood monocytes (34).
Monocyte survival in an AGE-β2M-containing
microenvironment is associated with phenotypic
alteration of the cells into macrophage-like cells that
generate more reactive oxygen species and elaborate
greater quantities of IL-1β and TNF-α (34). Thus,
through regulation of their survival and differentiation,
AGE-β2M in amyloid deposits may be able to influence
the presence and the quantity of infiltrated monocytes,
and hence their biologic effects. Advanced glycation end
product-β2M induces transforming growth factor
(TGF)-β1 production from human monocyte-derived
macrophages in vitro (35). Recently, Matsuo et al (35)
demonstrated that TGF-β1 and its receptors are localized
in the macrophages around AGE-modified amyloid
deposits in synovium of patients with DRA. This is of
interest because TGF-β is a potent chemotactic factor
for monocytes and might therefore contribute to
accumulation of monocytes in DRA.
In addition to the direct cellular chemotaxis and the
ability to stimulate the release of chemoattractants from
monocytes/macrophages, AGE-β2M may indirectly
recruit and activate monocytes/macrophages through
regulation of synoviocyte-derived chemokines. Very
recently, we examined the interaction of AGE-β2M with
human synovial fibroblasts, and the proinflammatory
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effects of this interaction (36). We found that RAGE is
expressed constitutively on the surface of synovial
fibroblasts and upregulated in synovial tissues from
patients with DRA. The interaction of AGE-β2M with
RAGE on synovial fibroblasts induces a marked increase
in expression of MCP-1, a potent monocyte chemo-
attractant and activator. The amount of MCP-1 produced
by AGE-β2M-stimulated synovial fibroblasts is sufficient
to induce monocyte recruitment in a chemotaxis analysis,
suggesting that RAGE-mediated perturbation of
synoviocytes might be involved in the pathogenesis of
cellular inflammatory processes associated with DRA
(36).
The evolution of inflammatory responses also involves
an interaction between adhesion molecules and cytokines
that results in leukocyte influx into inflammatory tissues.
We observed that TNF-α and IL-1β, abundant cytokines
in the synovial tissue of DRA, upregulate the expression
of intercellular adhesion molecule-1 and vascular cell
adhesion molecule-1 on cultured human synovial
fibroblasts (37). The up-regulation of these adhesion
molecules might be relevant in the recruitment of
monocytes expressing leukocyte function-associated
antigen-1 and Mac-1 from the peripheral blood to the
tissues of DRA. This finding is in agreement with the
histologic observation that synovial tissues from patients
with DRA strongly express intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1, and
a majority of macrophages in the perivascular area
express leukocyte function-associated antigen-1 and
Mac-1 (26,38).
Although several lines of evidence suggest pathobiologic
effects of AGE-β2M on other resident cells in
osteoarticular environments, such as osteoclasts (39), the
interrelationship between these cells and infiltrated
monocytes/macrophages has not been elucidated.
CONCLUSION
Cellular inflammation in DRA joints, characterized by
macrophage infiltration, may have a pivotal role in
transformation of clinically silent deposits into
symptomatic destructive arthropathy. The mechanism of
macrophage recruitment and activation is currently under
investigation. Higher plasma and synovial fluid levels
of β2M caused by chronic renal failure, and age-
dependent increases of AGEs in collagen may promote
β2M deposition in osteoarticular structures through
binding to AGE-modified collagen. Once β2M attach to
the matrix proteins, their continuous accumulation in
tissue may provide adequate time for AGE modification.
Several lines of evidence suggest that AGEs are endowed
with biologic activities that can partly account for
macrophage infiltration and accompanied arthropathies:
enhancing monocyte chemotaxis, inducing macrophage-
derived inflammatory cytokines, increasing TGF-β
expression, delaying monocyte apoptosis, and regulating
synoviocyte-derived chemokines. These findings suggest
that DRA arthropathies may result from progressive
accumulation of AGEs in long-lived amyloid linked to a
heightened cellular response.
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